Our Pricing

Wegovy Maintenance Dosage: Real UK Weight Loss Results

Published on: June 03, 2026

Searching for wegovy maintenance dose weight loss results uk data? At Cured Pharmacy, our UK clinical team has supported hundreds of patients through the full Wegovy journey, from titration to long-term maintenance. Clinical trials demonstrate that patients maintaining the 2.4mg weekly dose achieve sustained weight reduction of 15-17% over 68 weeks, with results persisting beyond the initial treatment phase when combined with lifestyle modifications [1].

What Is the Wegovy Maintenance Dose?

The Wegovy maintenance dose is 2.4mg semaglutide administered once weekly via subcutaneous injection [1]. Patients reach this dose after a 16-week titration schedule designed to minimise gastrointestinal side effects whilst building therapeutic efficacy. The gradual escalation begins at 0.25mg weekly, increasing every four weeks through 0.5mg, 1mg, and 1.7mg before reaching the full 2.4mg maintenance dose.

Once you've reached 2.4mg weekly, this becomes your ongoing maintenance dose for as long as treatment continues and remains clinically appropriate. In the STEP 1 trial, participants maintained on 2.4mg semaglutide achieved an average 14.9% body weight reduction at 68 weeks compared to 2.4% with placebo [1]. Importantly, weight loss plateaued around weeks 60-68, indicating a stable maintenance phase rather than continuous reduction.

Your UK prescriber will review your progress regularly to ensure the maintenance dose remains suitable. Some patients may require dose adjustments based on tolerability, side effects, or individual response, though 2.4mg weekly represents the standard licensed maintenance regimen for weight management in the UK [2].

Real UK Weight Loss Results on Wegovy Maintenance Dose

Clinical trial data provides the most robust evidence for Wegovy maintenance dose outcomes. In the landmark STEP 1 trial involving 1,961 adults with obesity or overweight plus weight-related comorbidities, participants on the 2.4mg maintenance dose lost an average 14.9% of their baseline body weight over 68 weeks [1]. For a 100kg patient, this translates to approximately 15kg sustained weight reduction.

Importantly, 86.4% of patients on the maintenance dose achieved at least 5% weight loss, whilst 69.1% achieved 10% or greater reduction and 50.5% reached 15% or more [1]. These response rates significantly exceeded placebo across all thresholds, demonstrating that the maintenance dose delivers clinically meaningful results for the majority of patients who reach and sustain this regimen.

Real-world UK data mirrors these trial findings. Our superintendent pharmacist Tarun Kumar notes that patients maintaining consistent 2.4mg weekly dosing alongside dietary modifications typically report sustained weight stability or modest continued reduction during months 5-12 of treatment. However, individual results vary considerably based on adherence, baseline metabolic health, physical activity levels, and genetic factors affecting semaglutide response.

Weight Loss Timeline on Maintenance Dose

Most patients experience their most rapid weight loss during the titration phase and first 8-12 weeks on the 2.4mg maintenance dose [1]. Weight reduction typically slows between weeks 60-68, reaching a plateau that represents your body's new equilibrium weight on treatment. This plateau is not treatment failure—it indicates you've reached the maximum benefit from your current regimen and lifestyle factors.

Continuing the maintenance dose beyond the initial plateau helps preserve weight loss. The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, whilst those continuing treatment maintained their reduction [3]. This underscores that Wegovy maintenance dosing is typically a long-term commitment rather than a short-term intervention.

How Long Should You Stay on Wegovy Maintenance Dose?

There is no predetermined endpoint for Wegovy maintenance treatment. MHRA licensing supports ongoing use for chronic weight management as long as clinical benefit persists and the medication remains well-tolerated [2]. Many patients continue the 2.4mg weekly dose for 12-24 months or longer, with regular reviews by their UK prescriber every 3-6 months.

NICE guidance suggests reviewing continuation at 6-12 months based on weight loss response and cardiovascular risk factor improvements [4]. If you've achieved less than 5% weight reduction after 6 months on the maintenance dose despite adherence and lifestyle modifications, your prescriber may recommend discontinuation or alternative approaches. Conversely, patients achieving and maintaining clinically significant weight loss may continue treatment indefinitely, subject to ongoing clinical appropriateness.

The decision to stop Wegovy should always involve your UK prescriber. Abrupt discontinuation typically leads to weight regain, as demonstrated in withdrawal studies [3]. Some clinicians explore dose reduction strategies or intermittent dosing schedules after prolonged maintenance, though these approaches lack robust trial evidence and are not part of standard UK prescribing protocols.

Maintaining Results After Stopping Wegovy

If you and your prescriber decide to discontinue Wegovy, transitioning to a structured weight maintenance programme is essential. Evidence suggests that patients who establish sustainable dietary patterns, regular physical activity routines, and behavioural strategies during treatment have better outcomes after cessation [3]. However, some weight regain is common and should be anticipated rather than viewed as personal failure.

Your UK clinical team can provide guidance on post-treatment weight management strategies, including ongoing nutritional support, physical activity planning, and monitoring for early signs of regain that might warrant treatment resumption. Some patients use Wegovy intermittently, restarting if weight increases beyond a predetermined threshold, though this approach requires careful medical supervision.

Managing Side Effects on Wegovy Maintenance Dose

Most patients tolerate the 2.4mg maintenance dose well, particularly if they've completed the full titration schedule without significant issues. However, gastrointestinal side effects including nausea, diarrhoea, constipation, and abdominal discomfort remain the most commonly reported adverse events even at maintenance dosing [1]. These effects are typically mild to moderate and often diminish over time as your body adapts.

In clinical trials, approximately 7% of patients discontinued semaglutide 2.4mg due to adverse events, primarily gastrointestinal symptoms [1]. If you experience persistent or severe side effects on the maintenance dose, your UK prescriber may consider temporary dose reduction to 1.7mg weekly, though this may compromise weight loss efficacy. Never adjust your dose without medical guidance.

Rare but serious side effects require immediate medical attention, including signs of pancreatitis (severe persistent abdominal pain), gallbladder problems, kidney impairment, or allergic reactions. Your prescriber will review your medical history to assess contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, which preclude Wegovy use [2].

Wegovy Maintenance Dose vs Other Weight Loss Treatments

Wegovy's 2.4mg maintenance dose delivers greater average weight reduction than older GLP-1 receptor agonists like liraglutide. In head-to-head comparisons, semaglutide 2.4mg produced approximately 6% greater weight loss than liraglutide 3mg over 68 weeks [2]. The once-weekly dosing schedule also offers significant convenience advantages over daily injections required for alternative treatments.

Newer dual GIP/GLP-1 receptor agonists have demonstrated even greater efficacy in clinical trials. However, each treatment has distinct characteristics, side effect profiles, and costs. Your UK prescriber will recommend the most appropriate option based on your medical history, treatment goals, previous medication responses, and individual circumstances.

Oral medications like orlistat offer an alternative mechanism but typically produce more modest weight reduction averaging 3-5% in clinical trials. These may suit patients who prefer to avoid injections or have contraindications to GLP-1 receptor agonists, though they require strict dietary fat restriction to minimise gastrointestinal side effects.

Combining Wegovy With Lifestyle Modifications

Wegovy maintenance dosing is most effective when combined with reduced-calorie diet and increased physical activity [1]. Clinical trials enrolled patients who received intensive behavioural interventions alongside medication, and real-world results may differ if lifestyle modifications are minimal. The medication facilitates adherence to dietary changes by reducing appetite and food cravings, but it does not replace the need for sustainable habit changes.

Your UK clinical team can provide guidance on evidence-based dietary approaches, though Wegovy does not require any specific diet type. Most patients find success with moderate calorie restriction (500-750 kcal daily deficit), increased protein intake to preserve lean muscle mass, and regular physical activity incorporating both cardiovascular exercise and resistance training. These lifestyle factors become particularly important if you eventually discontinue medication, as they form the foundation for long-term weight maintenance.

Starting Wegovy at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00 for UK patients who complete a free online consultation with our UK-registered prescribers. Our clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), reviews your medical history, current medications, and weight management goals to determine if Wegovy is clinically appropriate for your circumstances.

The consultation process takes under 3 minutes and covers essential safety screening including contraindications, previous weight loss attempts, and relevant medical conditions. If approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) with 100% discreet packaging and tracked delivery. We provide transparent upfront pricing before you begin the consultation, so you'll know exact costs before committing to treatment.

All Wegovy supplied through Cured Pharmacy is genuine UK-licensed medication sourced through regulated pharmaceutical supply chains. We never supply unlicensed imports or compounded alternatives. Your treatment includes ongoing support from our UK clinical team, with the option to message our pharmacists about dosing questions, side effect management, or treatment adjustments throughout your Wegovy journey.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/ [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual weight loss results vary and depend on multiple factors including adherence, lifestyle modifications, and metabolic characteristics. Wegovy does not cure obesity and is intended as part of a comprehensive weight management programme.